Bayer Corporate Newshttp://www.bayer.comWed, 16 May 2012 21:42:31 GMTBayer AG, Leverkusen, GermanyAll internationally relevant press releases from the Bayer Grouphttp://www.bayer.com/img/bayer-kreuz.gif Bayer Corporate Newshttp://www.bayer.com6767en"Lebenstagebuch" wins Aspirin Social Award 2012http://www.bayer.com/en/News-Detail.aspx?newsid=15965Thu, 10 May 2012 10:10:00 GMTBerlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care"Bayer has great potential for the future toohttp://www.bayer.com/en/News-Detail.aspx?newsid=15950Fri, 27 Apr 2012 07:59:00 GMTDr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG, and Supervisory Board Chairman Dr. Manfred Schneider (from left) just before the start of the 2012 Annual Stockholders’ Meeting in Cologne. ]]>Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG, and Supervisory Board Chairman Dr. Manfred Schneider (from left) just before the start of the 2012 Annual Stockholders’ Meeting in Cologne.Bayer AG, Leverkusen, GermanyEncouraging start to the year for Bayerhttp://www.bayer.com/en/News-Detail.aspx?newsid=15943Thu, 26 Apr 2012 05:30:00 GMTSales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmedPositive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat (for specialized target groups only)http://www.bayer.com/en/News-Detail.aspx?newsid=15938Wed, 25 Apr 2012 10:30:00 GMTFirst approval worldwide for EverGol™ in seed treatmenthttp://www.bayer.com/en/News-Detail.aspx?newsid=15916Fri, 20 Apr 2012 09:00:00 GMT ]]>Launch in Canada planned before the end of the yearBayer AG, Leverkusen, Germany